PharmInsider — The trade daily of the pharmaceutical industry.

Filing board Industry desk

30 open filings

Filing of the day

Active filings

6 cards

Pipeline log

  1. K-9861

    Alcohol Cuts Anti-PD-1 Efficacy Roughly 50% in Mouse Cancer Models

  2. C-9698

    FDA Clears GSK's Nelkarmi, Second Asset from $10.6B Nuvalent Deal

  3. K-8727

    FDA agrees 200-patient Phase 3 design for REC-4881 in FAP

  4. K-4971

    FDA Clears Roche's Wilserdly for Advanced Breast Cancer

  5. K-3717

    FDA Moves to Withdraw Approval of FloLipid Liquid Simvastatin

  6. C-7994

    FDA grants GSK accelerated approval for ALK inhibitor Nelkarmi

  7. K-8685

    FDA Clears Cosentyx for Polymyalgia Rheumatica, 11th US Indication

  8. P-1559

    FDA Hands Cipla's InvaGen New York Plant 'No Action Indicated' Status

Batch briefings